📉 Resilient Trader Trade Idea: The Oral Wegovy Re-Rating in Novo Nordisk (NVO)

Resilient Trader is where smart traders come for vetted ideas.

Every week, we cut through the noise and surface opportunities that institutions are already eyeing but with strategies tailored for retail traders. Today’s setup? A beaten-down healthcare leader with a monster obesity-drug franchise, a new consumer-direct access story, and a stock chart that finally looks like it may be waking up.

We’ll cover:

• Why Novo Nordisk is a Buy at current levels

• How to take advantage with defined risk through a straight call option

🔍 Trade Thesis: NVO Is a GLP-1 Leader the Market Left for Dead

Novo Nordisk (NVO) has been punished hard. The stock traded as high as $81.44 over the last year and recently closed at $44.74, which means investors have already priced in a lot of bad news.

But we think the market is missing the bigger picture.

Behind the scenes:

🚀 Oral Wegovy could change the game: If oral Wegovy through consumer-direct channels performs the way we think it can, it could generate roughly 2x consensus 2027 expectations and force analysts to raise numbers.

💊 Consumer-direct healthcare is weakening the middleman: Novo is pushing harder into patient access, savings programs, telehealth-style distribution and direct affordability models. That matters because obesity treatment is becoming a consumer-driven healthcare category, not just a traditional prescription-drug market.

🏥 Medicare could unlock a new demand wave: CMS materials point to a Medicare GLP-1 Bridge beginning July 1, 2026, with eligible beneficiaries gaining access to certain GLP-1 medications for $50 per month through December 31, 2027.

📊 GLP-1 adoption supports the broader healthcare ecosystem: More obesity-drug adoption should also drive more cardiometabolic monitoring, lab work and testing demand. But we prefer owning NVO here over diagnostic testing names because the drug platform has better upside, better margin structure and a cleaner re-rating path.

🎯 Our upside case: If the thesis plays out, NVO can trade back to a seven-handle - meaning a stock price starting with $70.

📊 The Fundamentals Are Still Strong

Let's break it down:

💰 Revenue: Novo generated DKK 309.1B in 2025 sales, up 6% reported and 10% at constant exchange rates.

📈 Obesity Care: Sales reached DKK 82.3B, up 26% reported and 31% at constant exchange rates. That is the engine of the story.

💉 Market Share: Novo held about 59.6% branded GLP-1 obesity volume share, while the global branded GLP-1 obesity market grew 104% by volume.

🧮 Profitability: Trailing operating margin was roughly 45%, and trailing net margin was roughly 37%, which is still elite for a company the market is treating like growth is dead.

💵 Cash Flow: Free cash flow fell during the investment cycle, but trailing free cash flow rebounded to about DKK 88.4B.

This is not a broken company. This is a high-quality growth franchise going through a sentiment reset.

📐 Valuation Has Reset

NVO is no longer priced like a market darling.

At $44.74, the stock trades near 10.5x trailing EPS using our USD/DKK conversion and current trailing earnings estimate. That is a major reset for a company with Novo’s brand power, global scale and GLP-1 leadership.

Why that matters:

⚖️ Base case: If the market simply gives NVO a modest recovery multiple, the stock can move into the high $50s or low $60s.

🏷️ Bull case: If oral Wegovy and Medicare access reignite growth expectations, NVO can trade back into the $70s.

📈 Analysts are not wildly bullish yet: MarketBeat shows an average price target of $65.56, with the stock still carrying a consensus Hold rating. That means the Street has room to get more constructive if the data improve.

🧭 Technicals Agree: This Chart Is Starting to Turn

This chart is not perfect yet, but it is improving.

✅ Current price: $44.74

✅ 20-day moving average: $43.27

✅ 50-day moving average: $39.98

⚠️ 100-day moving average: $45.73

⚠️ 200-day moving average: $49.13

🎯 Breakout zone: $48-$51

🎯 Bull target zone: $65-$75

NVO is now trading above its short-term moving averages, which tells us the bounce is real. The next key test is the $48-$51 area. A move through that zone would put the stock above recent resistance, near the option breakeven, and back on the radar for momentum traders.

🏥 Why We Prefer NVO Over Diagnostic Testing Names

We still believe GLP-1 adoption helps the broader healthcare ecosystem. More obesity treatment should mean more cardiometabolic monitoring, more blood work, more diabetes screening and more follow-up care.

But for this trade, we want the best expression of the theme.

That is why NVO is our preferred healthcare long exposure here. It gives us direct GLP-1 upside, a reset valuation, and a cleaner path to a major move if oral Wegovy works.

💥 Trade of the Week: NVO Stock + Straight Call

We’re combining a long equity idea with a defined-risk options trade for leveraged upside.

🟢 Trade Setup

• Buy $NVO ( ▼ 2.31% )  at $44.74 or better

This is the cleaner long-term trade. The stock has no expiration date, pays a dividend, and lets investors ride out volatility if the oral Wegovy and Medicare adoption story takes time to play out.

🛡️ Options Play

Buy the Dec. 18th $45 Call for $6.05

Option details:

• Buy Dec. 18th $45 Call: $6.05

• Net debit: $6.05

• Contract cost: $605

• Breakeven: $51.05

• Max loss: $605 per contract

• Max gain: Theoretically unlimited above breakeven

📈 Risk-Reward

This is a straight call, so the math is simple. If NVO closes below $45 at expiration, the option expires worthless. If it closes above $51.05, the trade is profitable at expiration.

This is why we like the call. If NVO merely grinds to $50, the option does not work. But if the stock moves toward our $65-$75 target zone, the payoff becomes very attractive.

🛑 Risk Management Tip

For the stock, we would watch the $38-$40 area. If NVO breaks back below that zone and fails to recover, the chart gets weaker and the trade needs to be reassessed.

For the call option, position size is everything. The maximum loss is 100% of the premium paid, so this should be sized as a defined-risk trade, not as a full stock replacement for conservative investors.

🚀 Catalysts on the Horizon

Keep your eyes on:

1. Oral Wegovy momentum - If oral Wegovy adoption comes in stronger than expected, consensus estimates likely need to move higher.

2. Medicare GLP-1 Bridge starting July 1 - Better affordability for eligible Medicare beneficiaries could materially expand adoption.

3. Consumer-direct healthcare trend - Direct access, telehealth distribution and cash-pay programs can weaken traditional intermediary structures.

4. Analyst upgrades - The current consensus is still cautious, which leaves room for upgrades if prescription and revenue trends improve.

5. Technical breakout - A move above $48-$51 could bring momentum buyers back into the name.

🧠 Final Thoughts

NVO is a classic case of a great company that got thrown into the penalty box.

The market is focused on pricing pressure, competition and slower growth. We think investors are underestimating the next leg: oral Wegovy, direct-to-consumer access, Medicare affordability and the broader GLP-1 adoption curve.

If we are right, NVO can move from the mid-$40s back into the $65–$75 range. That gives the common stock attractive upside, and it gives the Dec. 18th $45 call a strong asymmetric payoff.

✅ Buy NVO at $44.74 or better
💸 Buy the Dec. 18th $45 Call for $6.05 or better
🎯 Target zone: $65-$75
🧯 Risk zone to watch: $38-$40

We'll be watching this one closely.

Want more trade ideas like this - plus weekly options plays and breakdowns?

👉 Join the Paid Resilient Trader Newsletter

For more in-depth trading strategies and market insights, upgrade to the paid version of our newsletter.

Our paid newsletter gives you:

• Weekly stock + options trade ideas

  • Market commentary and macro insights

    • Easy-to-follow setups with defined risk

Stay Liquid, my friends and Happy New Year!
- The Resilient Trader